Effectiveness of a Digital Therapeutic on Type 2 Diabetes

Completed · Not applicable

Conditions studied: Type2 Diabetes

In brief

A clinical study evaluating a three month digitally delivered lifestyle change program in adults with Type 2 Diabetes. The FareWell Program (the "Program") aims to reduce well-established biomarkers of cardiometabolic diseases, weight, and medications. The current study is designed to evaluate to what degree adults with Type 2 Diabetes engaged with the Program can improve glycemic control and/or decrease medication needs.

Key facts

Study ID

NCT03369626

Run by

FareWell

People needed

118

Starts

2017-07-26

Expected to finish

2018-02-28

Last updated by the study team

2019-08-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• diagnosis of type 2 diabetes

You may not qualify if…

• Inability to understand, consent to, or comply with the study protocol for any reason, including inability to read or comprehend English.
• Does not have a smartphone (either an iPhone or Android phone)

Where it is running

• FareWell LLC — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.